(888) 800-9943 info@medtaskly.com
Book Free RCM Audit
Specialty Billing

Rheumatology Billing Services

Buy-and-bill biologics, JW modifier wastage reporting, and the 96365-96417 infusion hierarchy leave rheumatology practices exposed to five-figure denials on a single vial. Add strict prior auths and step therapy edits, and margins vanish fast. MedTaskly's AAPC-certified rheumatology billers protect every unit, every infusion, every claim.

Book Free RCM Audit
Quick Answer

Why are my rheumatology infusion claims for biologics like Remicade getting denied or underpaid?

Most rheumatology infusion denials trace to three errors: J-code units that do not match the dose administered, missing JW modifier documentation for discarded drug, and incorrect sequencing of infusion administration codes 96365-96417, where only one initial code is allowed per encounter. Payers also deny biologics outright when prior authorization or step therapy documentation is incomplete. Fixing unit math and admin-code hierarchy recovers most lost revenue.

Why It Matters

Where Rheumatology Practices Lose Revenue on Biologics and Infusions

One miscounted J-code unit can erase an entire infusion's margin.

Rheumatology medical billing lives and dies on the infusion suite. Buy-and-bill biologics require J-codes billed in exact units per vial, with discarded drug reported separately under the JW modifier, and a single wrong unit count can turn a profitable infusion into a loss. Administration coding adds another layer: the 96365-96417 hierarchy allows only one initial infusion code per encounter, and payers routinely down-code or deny claims where sequential and concurrent infusions are stacked incorrectly.

Then come the payer hurdles: strict prior authorizations for every biologic, step therapy requirements that force documented failure of preferred agents, and ultrasound guidance for joint injections under 20611 that gets denied without saved images and a separate written report. MedTaskly's AAPC-certified coders handle rheumatology billing for practices nationwide, verifying units, modifiers, and auths before submission, which is how we sustain a 98% clean-claim rate and faster, fuller infusion reimbursement.

What We Handle

End-to-end rheumatology billing revenue cycle

Buy-and-Bill J-Code Accuracy
We bill biologic J-codes in exact units per dose and vial size, so no drug revenue is left uncaptured or overbilled.
JW Modifier Wastage Reporting
Discarded drug from single-use vials is documented and billed with the JW modifier, recovering wastage payers otherwise refuse.
Infusion Hierarchy Coding 96365-96417
Initial, sequential, and concurrent infusion codes sequenced correctly per encounter, eliminating the down-coding that erodes infusion margins.
Biologic Prior Authorizations
We secure and track auths and step therapy documentation before the infusion, so expensive drugs are never administered unapproved.
Ultrasound-Guided Injection Billing
Joint injections with guidance billed under 20611 with image retention and report requirements met, preventing routine payer denials.
Denial Management and Appeals
Infusion and biologic denials worked within 48 hours, with unit, modifier, and medical necessity appeals backed by documentation.
FAQ

Rheumatology Billing Services — questions answered

What CPT and J-codes are most important in rheumatology billing?
The core set includes infusion administration codes 96365-96417, billed in a strict hierarchy with one initial code per encounter, plus drug-specific J-codes for biologics billed in exact units. Ultrasound-guided joint injections use 20611, which bundles the guidance. The JW modifier reports discarded drug from single-use vials. Getting units and sequencing right on these codes drives most rheumatology revenue.
Why do rheumatology infusion claims get denied so often?
The top causes are J-code unit errors, missing or misapplied JW modifiers for drug wastage, incorrect infusion code sequencing under 96365-96417, and biologics administered before prior authorization or step therapy requirements were satisfied. Guidance code 20611 also denies when images are not saved or a report is missing. Each is preventable with pre-submission verification.
How does MedTaskly handle prior authorizations and step therapy for biologics?
We verify benefits, submit prior authorization requests with the clinical documentation payers require, and track step therapy criteria showing failure of preferred agents before the drug is scheduled. Authorizations are monitored for expiration and visit limits, so infusions are never administered without active approval, protecting the practice from unrecoverable drug costs.
Can outsourced billing really improve margins on buy-and-bill drugs?
Yes. Buy-and-bill margins are thin, so recovering wastage through the JW modifier, billing exact J-code units, and preventing infusion down-coding directly increases yield per vial. Our clients benefit from a 98% clean-claim rate, which means fewer resubmissions, faster payment on high-dollar drug claims, and less cash tied up in accounts receivable.

Ready to stop losing revenue to denials?

Book a free, no-obligation RCM audit. We will show you exactly where your practice is leaking revenue and how to fix it.

Book Free RCM Audit
Or call us: (888) 800-9943